Health AI Central
Share:
Peer-Reviewed Publication
Int J Mol Sci2025;26(16)August 16, 2025Journal Article

BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome.

Sourat Darabi1, Phillip Stafford1,2,3, David R Braxton1, Carlos E Zuazo1, Taylor J Brodie1, Michael J Demeure1,4
1Hoag Family Cancer Institute, Newport Beach, CA 92663, USA.
2School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA.
3Fulgent Genetics, El Monte, CA 91731, USA.
4Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
PubMed PMC DOI PDF

Abstract

BRAF inhibitors have a 50-70% response rate in melanoma but are less effective for thyroid cancer. Differential response may be from activation or expression of downstream mitogen-activated protein kinase (MAPK) pathway genes. Retrospective analysis compared whole exome and transcriptome sequencing in melanoma and thyroid cancers from April 2019 to October 2023. The MAPK Activation Score (MPAS) wa…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.